Krystal Biotech Reports Q3 2025 Income Surge With Global VYJUVEK Expansion Planned

Krystal Biotech Inc reported strong financial results for Q3 2025, with net product revenue reaching $97.8 million, surpassing analyst estimates and representing a 17% increase from the prior year, driven primarily by sales of its flagship gene therapy product, VYJUVEK. The company achieved a high gross margin of 96% and posted net income of $79.4 million, or $2.74 per basic share, significantly exceeding expectations and reflecting operational efficiencies and a one-time tax benefit. VYJUVEK's commercial launch expanded into Germany, France, and Japan during 2025, with ongoing pricing negotiations in key European markets such as Germany and France expected to continue into 2026. Krystal Biotech is also building a specialty distributor network to support commercialization in regions like the Middle East and Central and Eastern Europe and is preparing regulatory filings for the UK and Switzerland. The company anticipates continued expansion of VYJUVEK's market reach and is advancing its product pipeline in respiratory, oncology, and dermatology. These strategic initiatives, supported by a strong balance sheet with $864.2 million in cash and investments, position Krystal Biotech for sustained growth and broader access to its therapies.